top of page
12
Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis BUndergoing Antiviral Treatments in a Real-World Setting
11
Systematic Review of Individual-Level Simulation in Cost-Effectiveness Analysis of Antiviral Treatments in Patients with Hepatitis B
10
Development of Scenarios By Health State to Measure the Quality of Life of Spinal Muscular Atrophy in the General Population
9
Use of the Narcotics Information Management System (NIMS) Data for Regulatory Science: Focusing on Methylphenidate Prescription
8
Application of External Comparators Using Rea-world Data in Healthcare Technology Assessment: Focusing on a Historical Cohort Example
7
Critical review of cost-effectiveness studies of nusinersen in patients with spinal muscular atrophy
6
Long-Term Cost-Effectiveness of Fractional Flow Reserve in Stable and Unstable Angina Patients
5
Differences in the Use of Medications for Treated ADHD patients between children and adults from Real-World Data in Korea
4
Assessment of adverse events following influenza vaccination using real-world big data
3
Nationwide prescription trends of methylphenidate in Korea using the Narcotics Information Management System data
2
Imbalanced Data Bias in Logistic Regression to Estimate Treatment Effects: Results from a Virtual Patient Cohort Simulation
1
Cost-effectiveness analysis for expanding the coverage of antiviral drugs in patients with untreated minimally active chronic hepatitis B
bottom of page